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Purpose: To translate and apply the Cataldo Lung Cancer Stigma Scale (CLCSS) for Chinese
populations and test the reliability and validity of the modified scale.
Method: A total of 150 lung cancer patients were recruited from three tertiary hospitals in
Shandong province and were tested using the Chinese version of CLCSS to assess its
reliability and validity.
Result: The Cronbach’s a coefficient of the Chinese version of CLCSS and the four subscales
ranged from 0.599 to 0.884, and the testeretest reliability ranged from 0.601 to 0.881. The
content validity index of the scale was 0.875. Four factors were extracted by exploratory
factor analysis that explained 58.6% of the total variance.
Conclusion: The Chinese version of CLCSS is a reliable and valid measure of stigma among
Chinese patients with lung cancer.
Copyright ª 2014, Chinese Nursing Association. Production and hosting by Elsevier
(Singapore) Pte Ltd. All rights reserved.1. Introduction
Stigma refers to disapproval of individuals due to undesirable
features such as special appearance, behaviour, or group
identity. Stigmas usually emerge under specific circum-
stances and situations such as drug abuse, AIDS,. Liu).
Nursing Association
g Association. Productionhomosexuality, and disability [1]. Health-related stigma (HRS)
is a perceived stigma that is characterized by experiences of
exclusion, rejection, blame from others, or diminished self-
worth [2]. Stigmatized individuals usually experience preju-
dice, discrimination, and isolation from others, which not
only disrupts daily life and social interactions. The conse-
quences of these stigmas also produce serious negativeand hosting by Elsevier (Singapore) Pte Ltd. All rights reserved.
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health [3e7].
Lung cancer is currently the most common form of cancer
and leading cause of cancer deaths in the world. In recent
years, studies have indicates there is a social stigma associ-
ated with lung cancer patients. Furthermore, compared with
other forms of cancer, lung cancer patients experience a larger
amount of psychological distress [8e11]. This stigma could
have negative impacts on the mental and physical health of
the lung cancer patients, leading to both strained social re-
lationships and an increase in patient mortality [2]. To better
understand this stigma and its effects on patients, Cataldo
developed the Cataldo Lung Cancer Stigma Scale (CLCSS) [2], a
reliable and valid measure of health-related stigma for lung
cancer patients. However, this stigma has not been
adequately studied in Chinese populations. In the present
study, we developed and evaluated a Chinese version of
CLCSS to identify the presence and impact of lung cancer
stigma in Chinese patients.2. Materials and methods
2.1. Patients
A total of 150 lung cancer patientswere randomly recruited for
this study. We collected data from departments of oncology,
thoracic surgery and respiratory in three Class III, Grade I
hospitals in Shandong province from June through September
2013. Participants were eligible to take part in the study if they
were age 20 years or older, diagnosed with lung cancer by
pathological examination, aware of their diagnosis, conscious
and also able to express their own opinions, and provided
informed consent.
During the stage of formal testing, a total of 150 Chinese
Cataldo Lung Cancer Stigma Scales in were distributed, and
124 were returned, among which 117 were considered usable.
Thus, the effective returns-ratio was 94%. The average patient
age was 58 (SD ¼ 3.2 years, range ¼ 23e82 years old), 86 pa-
tients were male and 31 were female. Twenty-nine patients
were diagnosed with stage I disease, 51 had stage II disease, 37
had stage III disease at the time of the survey.
2.2. Instruments
2.2.1. Chinese version of Cataldo Lung Cancer Stigma Scale
(CLCSS)
The CLCSS, developed in 2011, includes 31 items and 4 sub-
scales: stigma and shame, social isolation, discrimination,
and smoking status. Each stigma item was measured through
a four-point Likert-type scale ranging from 1 (strongly
disagree) to 4 (strongly agree) [2]. Higher scores indicate a
stronger feeling of stigma felt by the patient. Coefficient al-
phas ranged from 0.75 to 0.97 for the subscales (0.97 for stigma
and shame, 0.96 for social isolation, 0.92 for discrimination,
and 0.75 for smoking) and 0.96 for the CLCSS as a whole.
After obtaining approval from the original authors, the
CLCSS was translated independently by two English and
Chinese linguistic experts to produce a preliminary draft. The
translated draft was then translated back in to Chinese by anEnglish major and evaluated by a psychology expert, two
oncology clinical medical specialists, two oncology clinical
nurse specialists, and two nursing education experts to
determine whether the Chinese version of CLCSS could
accurately reflect the psychological status of Chinese lung
cancer patients. Based on their feedback, six items were
deleted from the scale. To stress on the locally special feature,
we gave open-end questionnaires to 30 lung cancer patients to
provide examples of experiencing a stigma. Six patients were
recruited for an in-depth interview, and after analysing and
concluding questionnaire and interview results, 13 new items
were added to the scale, bringing to total to 38 items. Twenty
patients with lung cancer were tested using the scale for a
preliminary experiment to assess the accuracy of each entry is
accurate. Further revisions were made based on the feedback
of the 20 patients to generate the final scale. Each stigma item
was measured using a four-point Likert-type scale ranging
from 1 (strongly disagree) to 4 (strongly agree). And 27 items
were scored inversely. Higher scores indicate a stronger
stigma feeling perceived by patients.
2.2.2. Criterion measuring tool
Criteria were measured based on the methods of Cataldo et al
[2]. Briefly, Rosenberg Self-esteem Scale (RSES) and Self-Rating
Depression Scale (SDS) were used as criterion measuring
tools. The RSES, the most commonly used self-esteem
measuring tool in modern psychology [12], has a coefficient
alpha of 0.84, indicating it is a reliable and valid measure. The
SDS includes 20 items and four subscales: spirituality e
emotional symptoms, physical disorder, spiritual movement
disorder, and distress.
2.3. Data collection
After obtaining the permission of hospitals and departments,
the researcher and assistants administered the questionnaires
to lung cancer patients who met the inclusion criteria, and
assistedpatientshavingdifficulty readingor complete thescale.
After obtaining permission of the patients and their relatives,
the in-depth interviews were carried out with the patients.
2.4. Statistical analysis
The scale was assessed using Cronbach’s alphas for internal
consistency, testeretest reliability measurements, content
validity analysis, factor analysis, parallel analysis, and crite-
rion validity. SPSS19.0 (SPSS INC, Chicago, IL, USA) statistical
software package was used in data processing including the
reliability measurement, exploratory factor analysis, and
Criterion-Related Validity. R statistical software (R Foundation
for Statistical Computing, Vienna, Austria) was used for par-
allel analysis data processing.3. Result
3.1. Project analysis
For each stigma-related item on the scale, patients were asked
to recall “since getting lung cancer, have I experienced the
Table 1 e Chinese version of Cataldo Lung Cancer Stigma Scale (n[ 117).
Item Loading R-square
A 1 I feel guilty because I have lung cancer.a 0.705 0.841
2 I think I am not disgrace for having cancer. 0.400 0.356
3 I work hard to keep my lung cancer a secret.a 0.607 0.654
4 I’m very careful whom I tell I have lung cancer.a 0.697 0.863
I’m afraid someone will tell others that I am suffering from lung cancer. 0.566 0.587
9 I feel I’m not as good as others because I have lung cancer.a 0.544 0.416
10 I feel set apart, isolated from the rest of the world.a 0.695 0.776
18 My lung cancer diagnosis was delayed because I put off going to the doctor.a 0.594 0.665
19 Some told me lung cancer is what I deserved for smoking.a 0.534 0.719
20 Some told me lung cancer is what I deserved for environment. 0.672 0.488
22 My lung cancer diagnosis was delayed because my healthcare provider
did not take my “smoker’s cough” seriously.a
0.528 0.48
24 Because I was suffering from lung cancer, I think I can’t what achievements
in life
0.523 0.502
26 I abandon myself because of suffering from lung cancer 0.572 0.648
27 Because I was suffering from lung cancer, the other people think that I
can’t what achievements in life
0.559 0.461
B 17 People I care about stopped calling after learning that I have lung cancer.a 0.614 0.723
7 People avoid touching me if they know I have lung cancer.a 0.575 0.721
11 I worry about people discriminating against me.a 0.546 0.608
12 People have physically backed away from me.a 0.646 0.828
13 People avoid you because lung cancer is associated with death.a 0.492 0.482
23 I was hurt how people reacted to learning I have lung cancer.a 0.619 0.689
C 14 That tell others I am suffering from lung cancer will bring big trouble for
me.
0.448 0.367
21 I worry that people may judge me when they learn I have lung cancer.a 0.543 0.662
25 Most are uncomfortable around someone with lung cancer.a 0.427 0.407
D 6 Others assume that a patient’s lung cancer was caused by smoking, even
if he or she never smoked.a
0.534 0.591
8 Lung cancer is viewed as a self-inflicted disease.a 0.451 0.478
15 Some people act as though it is my fault that I have lung cancer.a 0.46 0.364
16 Others assume that a patient’s lung cancer was caused by smoking, even if
he or she had stopped smoking years ago.
0.464 0.434
a A component of the original CLCSS.
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differentiation of the scale for each item. Significant differ-
ences were detected for all items except the 22nd, 23rd, 24th
items with correlations of 0.103, 0.125, and 0.131 respectively.
These three items were thus removed from further analysis.
These results indicate that the Chinese modified CLCSS gen-
erates statistically significant data with respect to item dif-
ferentiation scales.3.2. Validity test of the scale
3.2.1. Content validity
The expert panel determined that the 1st, 2nd, 6th, 7th, 8th,
30th, 35th items of the original CLCSS did not apply to Chinese
lung cancer patients, so these items were removed while
modifications to other items. For example, the phrase “I think
my situation is not as good as others because of the lung
cancer” was revised to “I think my situation is worse than
others because of the lung cancer”. The Content Validity Index
(CVI) were adopted to assess the validity of the scale, with a
CVI >0.7 indicating a valid scale. The CVI of the Chinese
version of Cataldo Lung Cancer Stigma Scale was 0.875,indicating that the Chinese CLCSS is a valid method for
measuring lung cancer stigma.
3.2.2. Exploratory factor analysis
The Kaiser-Meyer-Olkin (KMO) statistic of the sample in this
study was 0.752; The Bartlett Sphericity Test in this study was
2413.93 (Degrees of Freedom ¼ 378), which was statistically
significant (p < 0.01), indicating that factor analysis of the
Chinese CLCSS was appropriate. The principal component
analysis is using a mean eigenvalue curve indicates that there
were four eigenvalues in the screen plot above the mean
eigenvalue, so these four factors were retained. After rotation,
a single item with a factor loading of <0.4 was deleted, and
rotation was again performed. Four factors were extracted by
an exploratory analysis, these could explain 58.6% of the total
variance in the results (Table 1). These four factors were
stigma and shame, social isolation, discrimination, and
smoking status, which is in agreement with the original
CLCSS.
3.2.3. Criterion-Related Validity
Statistical analysis indicates that self-esteem scores corre-
lated negatively with the total stigma score and all subscales.
Table 2 e Criterion-Related Validity of Chinese version of CLCSS (n[ 117).
Total scale Stigma and shame Social isolation Discrimination Smoking
Rosenberg Self-esteem Scale 0.688** 0.670** 0.458** 0.441** 0.350**
Self-Rating Depression Scale 0.368** 0.361** 0.418** 0.372** 0.410**
*p < 0.05; **p < 0.01.
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related to the total scale scores and all subscales scores
(Table 2).3.3. Reliability test of the scale
3.3.1. Homogeneity reliability
The homogeneity reliability scores for our Chinese CLCSS are
provided in Table 3. The Cronbach’s a coefficient of the Chi-
nese version of CLCSS and the four primary factors ranged
from 0.599 to 0.868. The coefficient for the Chinese CLCSS as a
whole was 0.844. These data indicate that the Chinese CLCSS
is highly reliable.
3.3.2. Testeretest reliability
To assess testeretest reliability, we re-administered the
questionnaires to 40 extracted patients three weeks after the
initial survey. The resulting coefficient alpha of the total
stigma scale and the four primary factors was 0.880, 0.881,
0.788, 0.601, and 0.633 respectively. These results indicate a
high degree of consistency between repeat testing using the
Chinese CLCSS.4. Discussion
4.1. Validity evaluation of the scale
Following evaluation and revisions by a group of experts, we
demonstrate that the Chinese Version of the CLCSS can
accurately reflect the psychological status of the lung cancer
patients experiencing lung cancer-related stigmas. The CVI of
the scale was 0.875, higher than the reference value of 0.79,
indicating a high degree of content validity [13].
Four factors were extracted in an exploratory factor anal-
ysis that account for 58.6% of the total variance in our study,
similar to that of original CLCSS (57%) [2]. Criterion-Related
Validity shows that the questionnaire total score and each
factor were negatively correlated with Rosenberg Self-esteem
Scale (correlation coefficient ¼ 0.35w 0.688, p < 0.01), andTable 3 e Criterion-Related Validity of Chinese version of
CLCSS.
Dimensions Coefficient of alpha
CLCSS 0.884
Stigma and shame 0.868
Social isolation 0.818
Discrimination 0.599
Smoking 0.601the total score and individual factors were positively corre-
lated with Self-Rating Depression Scale (correlation
coefficient ¼ 0.361e0.418, p < 0.01). Based on these data, we
conclude that the Chinese CLCSS has a large degree of Crite-
rion-Related Validity.
4.2. Reliability evaluation of the scale
Internal consistency Cronbach’s alpha coefficient of the orig-
inal CLCSS is 0.656, which is used as a standard to compare to
ourmodified scale [14]. In our analysis, the coefficient alpha of
Chinese version of CLCSS and the individual subscales ranged
from 0.599 to 0.884, and the testeretest coefficient ranged
from 0.601 to 0.881, indicating that the Chinese CLCSS is both
highly valid and reliable for measuring the stigmas experi-
enced by lung cancer patients.
4.3. Limitations and shortcomings of the research
One limitation of this study is that relatively small sample
size. Our sample size was limited in scope, due in part to the
level of hospital from which the patient population was
selected. The depth of the survey sample was also limited
limitations, thereby limiting the reliability index of the Chi-
nese CLCSS. The number of patients who completed the
questionnaire and participated in in-depth interviews was
small, which could alter the distribution of items on the
scale. In China, especially in the northern region, for the
protection of patient’s physical and mental health, patients’
families often do not inform the patients that they are
suffering from lung cancer for fear that they will not partic-
ipate in the appropriate therapy, thus many patients were
unaware that they had lung cancer. In the case of our study,
the families were worried that the patient may have adverse
psychological implications after completing survey. These
factors all likely contributed to the limited sample size.
Another limitation was that the age of lung cancer patients is
generally high (average age is 58 years) and the reading
ability of this population is limited. Thus, parts of question-
naires were explained face to face to the patients by re-
searchers, which could affect the answers given by the
patients, leading to deviations in the process of measuring
the scale. Further refinements in survey methodology and
sample sizes will likely improve the accuracy of the Chinese
CLCSS.5. Summary
The Chinese version CLCSS is a reliable and valid measure of
social stigma experienced by Chinese lung cancer patients.
We found that lung cancer patients generally experience
i n t e r n a t i o n a l j o u r n a l o f nu r s i n g s c i e n c e s 1 ( 2 0 1 4 ) 2 3e2 7 27some form of social stigma as a result of their disease.
Our Chinese CLCSS could serve as a model for developing
methods for measuring cancer-related stigma in Chinese
populations. We hope that such studies could dramatically
improve patient outcomes for a variety of cancers patients in
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[1] Zhang BS, Yu GL. Stigma phenomenon and its psychological
effects. Adv Psychol Sci 2007;6:133e9.
[2] Cataldo JK, Slaughter R, Jahan TM, et al. Measuring stigma in
people with lung cancer: psychometric testing of the Cataldo
Lung Cancer Stigma Scale. Oncol Nurs Forum
2011;38(1):46e54.
[3] Van Rie A, Sengupta S, Pungrassami P, et al. Measuring
stigma associated with tuberculosis and HIV/AIDS in
southern Thailand: exploratory and confirmatory factor
analyses of two new scales. Trop Med Int Health
2008;13(1):21e30.
[4] Pan L, Liu GP. The research progress of public stigma of
mental illness. Chin J Nurs Educ 2013;10:42e4.
[5] Aranda-Naranjo B. Quality of life in the HIV-positive patient:
implications and consequences. J Assoc Nurs AIDS Care
2004;15(5 Suppl.):20e7.[6] Xing HY, Wen DH, Chen SM, et al. Reliability and validity of
Chinese version Zelaya’s HIV/AID stigma scale. Chin J Nurs
2012;47(12):1096e8.
[7] Schomerus G, Matschinger H, Angermeyer MC. The stigma of
psychiatric treatment and help-seeking intentions for
depression. Eur Arch Psychiatr Chin Neurosci
2009;259:298e306.
[8] Chapple A, Ziebland S, McPherson A. Stigma, shame, and
blame experienced by patients with lung cancer: qualitative
study. Br Med J 2004;328:1470e5.
[9] Calsen K, Jensen A, Jacobsen E, et al. Psychosocial aspects of
lung cancer. Lung Cancer 2005;47:293e300.
[10] LoConte NK, Else-Quest NM, Eickhoff J, et al. Assessment of
guilt and shame in patient with non-small-cell lung cancer
compared with patient with breast and prostate cancer. Clin
Lung Cancer 2008;9(3):171e8.
[11] Else-Quest N, LoConte N, Schiller J, et al. Perceived stigma,
self-blame, and adjustment among lung, breast, and prostate
cancer patient. Psychol Healthy 2009;24:949e64.
[12] Li H. The measurement of the mental health: the comparison
of self-esteem scale and the emotional scale. Psychol Dev
Educ 2004;2:77e81.
[13] Cheng L, Sun GZ, Li Z, et al. The cross-cultural adaptation of
the Dutch Objective Burden Inventory in a Chinese
population of caregivers for patients with chronic heart
failure. Chin J Nurs 2013;47:57e9.
[14] Guo JY, Li Z, Kang XF. The localization of the self-care index
of heart failure and the reliability and validity of the scale.
Chin J Nurs 2012;46:79e81.
